Our Recommendations
- Déclaration sur l’efficacité du vaccin COVID-19 d’AstraZeneca (ChAdOx1 nCoV-19) contre les variants du SARS-CoV-2 (2021)
- Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 (2021)
- Variants (2021)
- COVID Reference 2021.6 EN (2021)
- Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants (2021)
New Publications
- Update 80: What we know about new COVID-19 Variants of Concern - the latest on the global situation & Omicron BA.4/5 (2022)
- Fortalecendo a vigilância para a Variante de Preocupação (VOC) Ômicron (B.1.1.529): Informe técnico e ações prioritárias para estados-membros Sede da Organização Mundial da Saúde (2022)
- WHO’s Science in 5 Episode #64 - Why are experts concerned about Omicron? (2022)
- WHO’s Science in 5 Episode #63 - Omicron variant (2022)
- Методы обнаружения и описания вариантов SARS-CoV-2 – первое обновление. 20 декабря 2021 г. (2021)
Filter
37
Featured
Recommendations
8
Language
Document type
Fact sheets
17
Guidelines
6
Videos
6
Studies & Reports
3
Training Material
2
Resource Platforms
2
Manuals
1
Countries / Regions
Russia
3
Niger
2
Germany
2
West and Central Africa
2
France
2
Spain
2
East and Southern Africa
2
South Africa
2
Brazil
2
Mali
2
South Sudan
2
Colombia
1
Mexico
1
El Salvador
1
Turkey
1
Benin
1
Kazakhstan
1
Chile
1
Cameroon
1
Syria
1
Senegal
1
Congo-Brazzaville
1
Burkina Faso
1
Peru
1
Morocco
1
Qatar
1
Mauritania
1
Mozambique
1
Haiti
1
Dominican Republic
1
Venezuela
1
Latin America and the Carribbean
1
Jordan
1
Saudi Arabia
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
Tunisia
1
United Kingdom
1
Portugal
1
Belarus
1
Israel
1
Southern Africa
1
Côte d’Ivoire / Ivory Coast
1
Bolivia
1
Argentina
1
Lebanon
1
Vietnam
1
Eastern Europe
1
Nicaragua
1
Egypt
1
Sudan
1
Yemen
1
Honduras
1
Chad
1
Libya
1
Iraq
1
Somalia
1
Ecuador
1
India
1
Madagascar
1
Cuba
1
Guatemala
1
Authors & Publishers
Publication Years
Category
Countries
14
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian...
Weekly epidemiological update on COVID-19, 28 September 2022
WHO’s Science in 5 Episode #63 - Omicron variant
recommended
What do we know about Omicron variant so far? WHO's Dr Maria Van Kerkhove updates on the transmissibility, severity, symptoms and ways to protect yourself in Science in 5.
While COVID-19 virus continues to circulate and evolve, new variants are constantly emerging. Most of the current COVID-19 cases are driven by the circulation of the BA.5 subvariant of Omicron. The COVID-19 vaccines are being updated with Omicron variants to provide broader immunity against circulat...
Strengthening surveillance for Variant of Concern (VOC) Omicron (B.1.1.529): technical brief and priority actions for member states World Health Organization Headquarters, 28 November 2021
If Omicron is less severe, why are people ending up in the hospital and dying from it? Is it true that everyone will eventually get Omicron? Why is it important to reduce transmission? WHO's Dr Maria Van Kerkhove explains in Science in 5.
This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence of SARS-CoV-2 variants and outline a set of activities for the characterization and assessment of risk posed by these variants. A set of indicators ...
The NY Times variant tracker is perhaps the most accessible and relevant publication for non-molecular biologists and the general public
Each coronavirus contains nearly 30,000 letters of RNA. This genetic information allows the virus to infect cells and hijack them to make new viruses.
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
What are the variants circulating at this time? How are variants classified as variants of interest or concern? What does this mean for the public? Dr Maria Van Kerkhove explains in Science in 5 this week.
Do the current batch of approved vaccines protect us from the Delta variant? What is the level of protection? If you can still get infected even after being fully vaccinated, then why should we vaccinate? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
n light of the potential risk posed by SARS-CoV-2 variants, in January 2021 WHO organized an ad hoc consultation to discuss the development of an R&D agenda in response to existing and emerging SARS-CoV-2 variants.
The key objectives were to identify the critical research questions related to var...
A COVID-19 virus mutation tracker system (CovMT; appendix) based on SARS-CoV-2 isolate genomes deposited to GISAID to track the worldwide sequencing efforts and the evolution of the mutational landscape of this virus. CovMT, which is updated daily, summarises mutations from more than 450 000 isola...
21 Dec 2021. Slideset updated regularly to include the latest data and guidance on COVID-19 vaccines, including implications of emerging SARS-CoV-2 variants
This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence of SARS-CoV-2 variants and outline a set of activities for the characterization and assessment of risk posed by these variants. A set of indicators ...
Vertreter besorgniserregender Virusvarianten (variants of concern, kurz VOC) wurden weltweit aber auch in Europa, identifiziert. Molekularbiologische Details zu den Varianten sind unter SARS-CoV-2: Virologische Basisdaten und Virusvarianten abrufbar.
